Saeed Mohammadi

Saeed Mohammadi

Auto-generated profile, based on publicly available information

Saeed Mohammadi

Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
MMmohammad hossein Mohammadi
mohammad hossein Mohammadi
BMBehnam Molavi
Behnam Molavi
SMSaeed Mohammadi
Saeed Mohammadi
MNMohsen Nikbakht
Mohsen Nikbakht
AMAshraf Malek Mohammadi
Ashraf Malek Mohammadi
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh

20 April 2020 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
SMSaeed Mohammadi
Saeed Mohammadi
SYSeyed Morteza Tabatabaei Yazdi
Seyed Morteza Tabatabaei Yazdi
PEPeyman Eshghi
Peyman Eshghi
ANAmir Hossein Norooznezhad
Amir Hossein Norooznezhad

1 December 2020 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
SBSahar Balagholi
Sahar Balagholi
RDRasul Dabbaghi
Rasul Dabbaghi
PEPeyman Eshghi
Peyman Eshghi
SMSeyed Asadollah Mousavi
Seyed Asadollah Mousavi
FHFarhad Heshmati
Farhad Heshmati
SMSaeed Mohammadi
Saeed Mohammadi

1 April 2017 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
SMSaeed Mohammadi
Saeed Mohammadi
SNShirzad Nasiri
Shirzad Nasiri
MMmohammad hossein Mohammadi
mohammad hossein Mohammadi
AMAshraf Malek Mohammadi
Ashraf Malek Mohammadi
MNMohsen Nikbakht
Mohsen Nikbakht
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh

1 November 2017 in Wound Repair and Regeneration
Verified
Journal Article
Closed access
PDF file
SMShayan Mostafaei
Shayan Mostafaei
FNFatemeh Norooznezhad
Fatemeh Norooznezhad
SMSaeed Mohammadi
Saeed Mohammadi
ANAmir Hossein Norooznezhad
Amir Hossein Norooznezhad

1 October 2018 in Genetic Testing and Molecular Biomarkers
Verified
Journal Article
Closed access
MIMarzieh Izadifard
Marzieh Izadifard
HPHossein Pashaiefar
Hossein Pashaiefar
MYMarjan Yaghmaie
Marjan Yaghmaie
MMMaryam Montazeri
Maryam Montazeri
MSMaryam Sadraie
Maryam Sadraie
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
Recent evidence indicates that the PVT1, CCDC26, and CCAT1 long noncoding RNAs (lncRNAs) are involved in the leukemogenic process. This study quantified the expression levels of the PVT1, CCDC26, and CCAT1 lncRNAs in patients with acute myeloid leukemia (AML) and also correlated their expression levels with the clinicopathological features of the patients. The expression levels of the PVT1, CCDC26, and CCAT1 lncRNAs were analyzed using quantitative reverse transcription-polymerase chain reaction of bone marrow specimens obtained from 86 AML patients, 48 AML-M3 patients, and 40 normal controls. No differences were found between the combined AML patient populations and the healthy controls with respect to the expression levels of PVT1, CCDC26, and CCAT1 (p = 0.35, p = 0.09, and p = 0.77, respectively). However, compared with the controls, the AML-M3 patients had higher PVT1 expression (p = 0.017). Furthermore, high-risk AML-M3 patients manifested higher expression levels of PVT1 than low- and intermediate-risk groups. In addition, distinctive CCDC26 and CCAT1 expression levels were observed among patients with different French-American-British subtypes (p = 0.001 for CCDC26 and p = 0.013 for CCAT1). Compared with the healthy controls, AML-M4 and M5 had higher CCAT1 expression (p = 0.04) and AML-M2 and AML-M4/M5 patients had higher CCDC26 expression (p < 0.001 and p = 0.02, respectively). In addition, different patterns of CCDC26 expression were found among the different cytogenetic risk subtypes (p = 0.005). Finally, patients with intermediate cytogenetic risk showed higher CCDC26 expression levels. The differential expression of the PVT1, CCDC26, and CCAT1 lncRNAs in different AML subtypes suggests that the deregulation of these transcripts may function in the multistep leukemogenic process and that they may serve as new therapeutic targets for this malignancy.